Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)

Trial Profile

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Abemaciclib (Primary) ; Cobimetinib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Enasidenib (Primary) ; Erdafitinib (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary) ; Venetoclax (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MyDRUG
  • Most Recent Events

    • 11 Dec 2018 Planned End Date changed from 10 Dec 2023 to 10 Feb 2024.
    • 11 Dec 2018 Planned primary completion date changed from 10 Dec 2021 to 10 Feb 2022.
    • 11 Dec 2018 Planned initiation date changed from 10 Dec 2018 to 10 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top